Dividend Assets Capital LLC lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 284,890 shares of the medical instruments supplier’s stock after acquiring an additional 14,609 shares during the period. Becton, Dickinson and accounts for 2.2% of Dividend Assets Capital LLC’s portfolio, making the stock its 13th biggest holding. Dividend Assets Capital LLC owned about 0.13% of Becton, Dickinson and worth $55,585,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in Becton, Dickinson and by 2,427.8% in the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after buying an additional 15,887,611 shares in the last quarter. Vanguard Group Inc. grew its position in Becton, Dickinson and by 5.3% in the 1st quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock valued at $2,917,094,000 after buying an additional 796,034 shares in the last quarter. Point72 Asset Management L.P. bought a new position in Becton, Dickinson and in the 1st quarter valued at about $101,993,000. Waverton Investment Management Ltd bought a new position in Becton, Dickinson and in the 2nd quarter valued at about $68,448,000. Finally, Montag & Caldwell LLC grew its position in Becton, Dickinson and by 173.1% in the 2nd quarter. Montag & Caldwell LLC now owns 516,821 shares of the medical instruments supplier’s stock valued at $100,837,000 after buying an additional 327,587 shares in the last quarter. Institutional investors and hedge funds own 87.43% of the company’s stock.

In other Becton, Dickinson and news, EVP Linda M. Tharby sold 4,695 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $200.48, for a total transaction of $941,253.60. Following the transaction, the executive vice president now owns 18,670 shares in the company, valued at $3,742,961.60. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the transaction, the insider now owns 95,781 shares in the company, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. Over the last quarter, insiders sold 75,904 shares of company stock valued at $15,242,688. Corporate insiders own 1.40% of the company’s stock.

BDX has been the subject of a number of recent analyst reports. BidaskClub lowered shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Bank of America Corporation reiterated a “buy” rating and issued a $225.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price for the company in a research report on Monday, July 17th. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $213.00 target price on shares of Becton, Dickinson and in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, five have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $196.93.

TRADEMARK VIOLATION NOTICE: This news story was published by Daily Political and is the property of of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/09/14/dividend-assets-capital-llc-purchases-14609-shares-of-becton-dickinson-and-company-bdx.html.

Shares of Becton, Dickinson and Company (BDX) opened at 196.62 on Thursday. The stock has a market capitalization of $44.74 billion, a price-to-earnings ratio of 56.94 and a beta of 1.06. The firm’s 50-day moving average is $199.98 and its 200-day moving average is $191.16. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the Zacks’ consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company’s revenue was down 5.1% on a year-over-year basis. During the same period last year, the company earned $2.35 earnings per share. On average, analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be given a $0.73 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.49%. Becton, Dickinson and’s payout ratio is 83.43%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.